In contrast, high expression of FRZB, MYBL2, MYL2, NETO2, PLSCR4, and TES predicts an unfavorable outcome in endometrial, head and neck, liver, pancreatic, and renal cancer. This evidence concerns the gene NETO2 and renal carcinoma.